Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.

The multicenter study includes 180 subjects sensitised to cupressaceae and grass pollen, both male and female aged 12 to 65 years. The double-blinded and placebo controlled treatment will last 18 months for each subject. The primary endpoint of the trial will be the combined rhinitis/rhinoconjunctivitis symptom and medication score (RCSMS) which will be assessed using data collected in the Subject electronic Diary during the cupressaceae (January, February and March) and grass (May and June) pollen seasons.